Data from the phase 3 MIRASOL trial support the full FDA approval of mirvetuximab soravtansine for those with folate receptor alpha–positive platinum-resistant ovarian cancer.
Approval Alert | Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
Prophylaxis and Practical Implementation of the COPERNICUS Approach
2
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
Fecal Microbiota Transplantation Shows Feasibility in Metastatic RCC
5